Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives. Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

Table of Contents

1. Introduction to immunotherapy: History of immune therapy in cancer2. Infiltrating immune mass in cancer: what is beyond T lymphocytes3. Immunotherapy and macrophages 4. Immune checkpoints in different types of cancer: Where and when5. Immune cocktails in solid tumors6. Immunotherapy as adjuvant modality7. Immuno-phenotyping as a diagnosis in cancer: Is it useful in pathology? 8. Immunoresistance: Basic and clinical data9. Glycosylation: Implications for resistance to immune therapy

Authors

Jorge Morales-Montor Chair and head of Department of Neuroinmunoendocrinology, Institute of Biomedical Research, National Autonomous University of Mexico, (UNAM). Dr. Jorge Morales-Montor is the head of the Department of Neuroinmunoendocrinology at UNAM. In addition, at the moment he is the Editor in Chief of the journal Advances in Neuroimmune Biology. His laboratory has been interested in translational research and novel therapeutics in cancer, and other chronic degenerative diseases. He has expertise in leadership and training. Lately, he is focused on the immune alteration by endocrine disruptors in breast cancer. Mariana Segovia-Mendoza Associate Professor, Departamento de Farmacologia, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. Dr. Mariana Segovia Mendoza has extensive expertise in the subject of breast cancer and hormones. She also has collaborated with international groups. At the moment, she collaborates in the working lab group of Dr. Morales researching the infiltrating immune cells and their alterations by endocrine disruptor compounds in patients with breast cancer. Recently, she has published an article on this topic to expand the information as well as to accurately address different therapeutic options in an immuno-dependent manner.